Close X
Attorney Spotlight

How did a clerkship with Judge Merritt change the way Chris Climo approaches the practice of law? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Primary Care Providers Win Challenge of CMS Interpretation of Enhanced Payment Law

With the help and support of the Tennessee Medical Association, 21 Tennessee physicians of underserved communities joined together and retained Bass, Berry & Sims to file suit against the Centers for Medicare & Medicaid Services to stop improper collection efforts. Our team, led by David King, was successful in halting efforts to recoup TennCare payments that were used legitimately to expand services in communities that needed them. Read more

Tennessee Medical Association & Bass, Berry & Sims

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Download the Healthcare Fraud & Abuse Review 2017, authored by Bass, Berry & Sims

The Healthcare Fraud & Abuse Review 2017 details all healthcare-related False Claims Act settlements from last year, organized by particular sectors of the healthcare industry. In addition to reviewing all healthcare fraud-related settlements, the Review includes updates on enforcement-related litigation involving the Stark Law and Anti-Kickback Statute, and looks at the continued implications from the government's focus on enforcement efforts involving individual actors in connection with civil and criminal healthcare fraud investigations.

Click here to download the Review.

John Kelly Comments on FCPA in the Foreign Pharmaceutical and Medical Device Industry on Thomson Reuters

Reuters.com

Media Mentions

May 10, 2012

Bass, Berry & Sims healthcare fraud attorney, John Kelly, comments on the recent DOJ and SEC investigations of nearly every major pharmaceutical and medical device manufacturer regarding potential violations of the Foreign Corrupt Practices Act (FCPA) after an Indian parliamentary panel alleged abuses in the country's drug approval process. The DOJ has also shown interest in examination of potential corruption in the clinical trials process.

"With clinical trials, you're going to have constant interaction with either foreign officials or entities that are operated by government entities," John Kelly said. "If they weren't (looking at it), they will be now."

The full article published by Thomson Reuters and titled "India drugs inquiry could prompt new U.S. scrutiny," can be found here.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.